TESAMORELIN

So What Does This Actually Mean?

Plain English summary — no PhD required

Tesamorelin is a synthetic version of GHRH (growth hormone-releasing hormone) that has actually been FDA-approved since 2010. It's sold under the brand name Egrifta® for reducing excess abdominal fat in HIV patients on antiretroviral therapy. This makes it one of the few peptides in this guide with genuine FDA approval and published Phase III clinical trial data.

What It Does

Like CJC-1295, Tesamorelin stimulates the pituitary gland to release growth hormone by mimicking the natural GHRH signal. The key difference is its specific clinical validation for visceral fat reduction. In FDA-approved trials, Tesamorelin produced statistically significant reductions in trunk fat in HIV patients, with effects maintained over 52 weeks of treatment. It works through the GH/IGF-1 axis, which regulates fat metabolism alongside muscle and bone effects.

Why It Matters

Visceral fat (the fat stored around internal organs) is metabolically distinct from subcutaneous fat and is strongly associated with cardiovascular and metabolic disease risk. Tesamorelin's FDA approval for visceral fat reduction gives it a level of clinical credibility that most research peptides lack. Researchers studying metabolic syndrome, lipodystrophy, or GH axis biology have a robust clinical dataset to reference.

The Bottom Line

Tesamorelin is unique in this catalog because it has FDA approval for a specific indication, meaning it has completed the full clinical trial process. The research-grade lyophilized powder supplied by Purgo Labs is for laboratory use only and differs from the clinical formulation. Its approval status makes it one of the most clinically validated GHRH analogs available for research.

Overview

What is Tesamorelin?

Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH) consisting of the full 44-amino-acid sequence of GHRH with a trans-3-hexenoic acid group conjugated to the N-terminus. This modification significantly enhances metabolic stability compared to native GHRH while preserving full biological activity at the GHRH receptor.

Tesamorelin is notable for being the only GHRH analog to receive FDA approval. It is approved under the brand name Egrifta® for the reduction of excess visceral adipose tissue (VAT) in HIV-infected patients with antiretroviral therapy-associated lipodystrophy. This clinical validation provides a robust human pharmacokinetic, pharmacodynamic, and safety dataset that distinguishes tesamorelin from most research peptides. By stimulating GH release and downstream insulin-like growth factor (IGF-1) production, tesamorelin supports improvements in body composition. This includes reductions in fat stored around the abdomen and preservation of lean muscle mass, making it a subject of interest in metabolic and anti-aging research.

Key Takeaways

• Tesamorelin is a stabilized synthetic GHRH analog — the only GHRH analog with FDA approval (Egrifta®, 2010) for reducing excess visceral abdominal fat in HIV-associated lipodystrophy

• Mechanism: binds pituitary GHRH receptors to stimulate pulsatile GH release, which drives IGF-1 production and preferential visceral fat lipolysis

• Phase III clinical data: statistically significant trunk fat reduction maintained over 52 weeks; one of the most robust clinical datasets for any GHRH analog

• Half-life ~26 minutes (shorter than CJC-1295 DAC); requires daily subcutaneous injection in clinical use

• Research-grade lyophilized powder for laboratory use only; differs from the clinical Egrifta® formulation; WADA-prohibited

Composition

Molecular Composition

Amino Acid Sequence

trans-3-hexenoic acid-YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL (44 AA)

Tesamorelin consists of the complete 44-amino-acid sequence of human GHRH (hGHRH[1-44]-NH2) with a trans-3-hexenoic acid moiety conjugated to the alpha-amino group of the N-terminal tyrosine residue. This N-terminal modification is the key structural feature that confers enhanced stability against dipeptidyl peptidase IV (DPP-IV) cleavage — the primary mechanism of native GHRH degradation.

The molecular weight is 5,135.9 Daltons. Unlike CJC-1295, which achieves stability through amino acid substitutions, tesamorelin achieves stability through the N-terminal fatty acid conjugation while retaining the complete native GHRH sequence.

Mechanism of Action

How Does It Work?

!

Tesamorelin reduces visceral fat by stimulating pulsatile growth hormone release, which activates lipolysis specifically in abdominal adipose tissue.

Tesamorelin acts as a selective agonist at the GHRH receptor (GHRHR) on pituitary somatotroph cells, activating the same adenylyl cyclase → cAMP → PKA signaling cascade as native GHRH. This triggers the synthesis and pulsatile release of endogenous growth hormone, which in turn stimulates hepatic IGF-1 production.

The mechanism underlying tesamorelin's specific effect on visceral adipose tissue (VAT) involves GH-mediated stimulation of lipolysis in visceral fat depots. GH activates hormone-sensitive lipase (HSL) in adipocytes, promoting the breakdown of stored triglycerides. Visceral adipocytes are particularly sensitive to GH-mediated lipolysis due to their higher density of GH receptors and lower sensitivity to insulin's anti-lipolytic effects compared to subcutaneous adipocytes.

Tesamorelin Mechanism of Action — Simplified signaling pathway diagram. For research reference only.

"Tesamorelin significantly reduced visceral adipose tissue and improved metabolic parameters in HIV-infected patients with lipodystrophy, demonstrating the therapeutic potential of targeted GHRH receptor activation." — Falutz et al., New England Journal of Medicine, 2010